Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden.


Journal

Clinical colorectal cancer
ISSN: 1938-0674
Titre abrégé: Clin Colorectal Cancer
Pays: United States
ID NLM: 101120693

Informations de publication

Date de publication:
06 2023
Historique:
received: 21 04 2022
revised: 06 02 2023
accepted: 07 02 2023
medline: 26 5 2023
pubmed: 7 3 2023
entrez: 6 3 2023
Statut: ppublish

Résumé

Fecal Immunochemical Test (FIT) is widely used in population-based screening for colorectal cancer (CRC). This had led to major challenges regarding colonoscopy capacity. Methods to maintain high sensitivity without compromising the colonoscopy capacity are needed. This study investigates an algorithm that combines FIT result, blood-based biomarkers associated with CRC, and individual demographics, to triage subjects sent for colonoscopy among a FIT positive (FIT From the Danish National Colorectal Cancer Screening Program, 4048 FIT The discrimination of CRC showed an area under the curve (AUC) of 73.7 (70.5-76.9) for the predefined model, 75.3 (72.1-78.4) for the exploratory model, and 68.9 (65.5-72.2) for FIT alone. Both models performed significantly better (P < .001) than the FIT model. The models were benchmarked vs. FIT at cutoffs of 100, 200, 300, 400, and 500 ng/mL Hemoglobin using corresponding numbers of true positives and false positives. All performance metrics were improved at all cutoffs. A screening algorithm including a combination of FIT result, blood-based biomarkers and demographics outperforms FIT in discriminating subjects with or without CRC in a screening population with FIT results above 100 ng/mL Hemoglobin.

Sections du résumé

BACKGROUND
Fecal Immunochemical Test (FIT) is widely used in population-based screening for colorectal cancer (CRC). This had led to major challenges regarding colonoscopy capacity. Methods to maintain high sensitivity without compromising the colonoscopy capacity are needed. This study investigates an algorithm that combines FIT result, blood-based biomarkers associated with CRC, and individual demographics, to triage subjects sent for colonoscopy among a FIT positive (FIT
MATERIALS AND METHODS
From the Danish National Colorectal Cancer Screening Program, 4048 FIT
RESULTS
The discrimination of CRC showed an area under the curve (AUC) of 73.7 (70.5-76.9) for the predefined model, 75.3 (72.1-78.4) for the exploratory model, and 68.9 (65.5-72.2) for FIT alone. Both models performed significantly better (P < .001) than the FIT model. The models were benchmarked vs. FIT at cutoffs of 100, 200, 300, 400, and 500 ng/mL Hemoglobin using corresponding numbers of true positives and false positives. All performance metrics were improved at all cutoffs.
CONCLUSION
A screening algorithm including a combination of FIT result, blood-based biomarkers and demographics outperforms FIT in discriminating subjects with or without CRC in a screening population with FIT results above 100 ng/mL Hemoglobin.

Identifiants

pubmed: 36878807
pii: S1533-0028(23)00006-3
doi: 10.1016/j.clcc.2023.02.001
pii:
doi:

Substances chimiques

antigen CYFRA21.1 0
Hemoglobins 0
Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-210

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure Gerard Davis, Susan Gawel and Frans Martens are all employees of Abbott Laboratories Inc. All other authors declare that they have no competing interest.

Auteurs

Mathias M Petersen (MM)

Gastro Unit, Hvidovre Hospital, Hvidovre, Denmark; Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address: mathias.mertz.petersen@regionh.dk.

Jakob Kleif (J)

Gastro Unit, Hvidovre Hospital, Hvidovre, Denmark; Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Surgery, Nordsjællands Hospital, Hillerød, Denmark.

Lars N Jørgensen (LN)

Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Digestive Disease Center, Bispebjerg Hospital, Copenhagen, Denmark.

Jakob W Hendel (JW)

Gastro Unit, Section for Gastroenterology, Herlev Hospital, Herlev, Denmark.

Jakob B Seidelin (JB)

Gastro Unit, Section for Gastroenterology, Herlev Hospital, Herlev, Denmark.

Mogens R Madsen (MR)

Department of Surgery, Herning Hospital, Herning, Denmark.

Jesper Vilandt (J)

Department of Surgery, Nordsjællands Hospital, Hillerød, Denmark.

Søren Brandsborg (S)

Department of Surgery, Horsens Hospital, Horsens, Denmark.

Jørn S Rasmussen (JS)

Department of Surgery, Horsens Hospital, Horsens, Denmark.

Lars M Andersen (LM)

Department of Public Health Programmes and University Research Clinic for Cancer Screening, Randers Regional Hospital, Randers, Denmark.

Ali Khalid (A)

Department of Surgery, Viborg Hospital, Viborg, Denmark.

Linnea Ferm (L)

Gastro Unit, Hvidovre Hospital, Hvidovre, Denmark.

Susan H Gawel (SH)

Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL.

Frans Martens (F)

Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam UMC, AMC & VUMC, Amsterdam, The Netherlands.

Berit Andersen (B)

Department of Public Health Programmes and University Research Clinic for Cancer Screening, Randers Regional Hospital, Randers, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Morten Rasmussen (M)

Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Gerard J Davis (GJ)

Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL.

Ib J Christensen (IJ)

Gastro Unit, Hvidovre Hospital, Hvidovre, Denmark.

Christina Therkildsen (C)

Gastro Unit, Hvidovre Hospital, Hvidovre, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH